Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226156918> ?p ?o ?g. }
- W4226156918 endingPage "269" @default.
- W4226156918 startingPage "259" @default.
- W4226156918 abstract "Background Trastuzumab is a monoclonal antibody against HER2 (also known as ERBB2). The primary objective of the NRG Oncology/RTOG-1010 trial was to establish whether trastuzumab improves disease-free survival when combined with trimodality treatment (paclitaxel plus carboplatin and radiotherapy, followed by surgery) for patients with untreated HER2-overexpressing oesophageal adenocarcinoma. Methods NRG Oncology/RTOG-1010 was an open label, randomised, phase 3 trial for which patients were accrued from 111 NRG-affiliated institutions in the USA. Eligible patients were adults (aged ≥18 years) with newly diagnosed pathologically confirmed oesophageal adenocarcinoma, American Joint Committee on Cancer 7th edition T1N1–2 or T2–3N0–2 stage disease, and a Zubrod performance status of 0–2. Patients were stratified by adenopathy (no vs yes [coeliac absent] vs yes [coeliac present ≤2 cm]) and randomly assigned (1:1) to receive weekly intravenous paclitaxel (50 mg/m2 intravenously over 1 h) and carboplatin (area under the curve 2, intravenously over 30–60 min) for 6 weeks with radiotherapy 50·4 Gy in 28 fractions (chemoradiotherapy) followed by surgery, with or without intravenous trastuzumab (4 mg/kg in week one, 2 mg/kg per week for 5 weeks during chemoradiotherapy, 6 mg/kg once presurgery, and 6 mg/kg every 3 weeks for 13 treatments starting 21–56 days after surgery). The primary endpoint, disease-free survival, was defined as the time from randomisation to death or first of locoregional disease persistence or recurrence, distant metastases, or second primary malignancy. Analyses were done by modified intention to treat. This study is registered with Clinicaltrials.gov, NCT01196390; it is now closed and in follow-up. Findings 606 patients were entered for HER2 assessment from Dec 30, 2010 to Nov 10, 2015, and 203 eligible patients who were HER2-positive were enrolled and randomly assigned to chemoradiotherapy plus trastuzumab (n=102) or chemoradiotherapy alone (n=101). Median duration of follow-up was 2·8 years (IQR 1·4–5·7). Median disease-free survival was 19·6 months (95% CI 13·5–26·2) with chemoradiotherapy plus trastuzumab compared with 14·2 months (10·5–23·0) for chemoradiotherapy alone (hazard ratio 0·99 [95% CI 0·71–1·39], log-rank p=0·97). Grade 3 treatment-related adverse events occurred in 41 (43%) of 95 patients in the chemoradiotherapy plus trastuzumab group versus 52 (54%) of 96 in the chemoradiotherapy group and grade 4 events occurred in 20 (21%) versus 21 (22%). The most common grade 3 or worse treatment-related adverse events for both groups were haematological (53 [56%] of 95 patients in the chemoradiotherapy plus trastuzumab group vs 55 [57%] of 96 patients in the chemotherapy group) or gastrointestinal disorders (28 [29%] vs 20 [21 %]). 34 (36%) of 95 patients in the chemoradiotherapy plus trastuzumab group and 27 (28%) of 96 patients in the chemoradiotherapy only group had treatment-related serious adverse events. There were eight treatment-related deaths: five (5%) of 95 patients in the chemoradiotherapy plus trastuzumab group (bronchopleural fistula, oesophageal anastomotic leak, lung infection, sudden death, and death not otherwise specified), and three (3%) of 96 in the chemoradiotherapy group (two multiorgan failure and one sepsis). Interpretation The addition of trastuzumab to neoadjuvant chemoradiotherapy for HER2-overexpressing oesophageal cancer was not effective. Trastuzumab did not lead to increased toxicities, suggesting that future studies combining it with or using other agents targeting HER2 in oesophageal cancer are warranted. Funding National Cancer Institute and Genentech. Trastuzumab is a monoclonal antibody against HER2 (also known as ERBB2). The primary objective of the NRG Oncology/RTOG-1010 trial was to establish whether trastuzumab improves disease-free survival when combined with trimodality treatment (paclitaxel plus carboplatin and radiotherapy, followed by surgery) for patients with untreated HER2-overexpressing oesophageal adenocarcinoma. NRG Oncology/RTOG-1010 was an open label, randomised, phase 3 trial for which patients were accrued from 111 NRG-affiliated institutions in the USA. Eligible patients were adults (aged ≥18 years) with newly diagnosed pathologically confirmed oesophageal adenocarcinoma, American Joint Committee on Cancer 7th edition T1N1–2 or T2–3N0–2 stage disease, and a Zubrod performance status of 0–2. Patients were stratified by adenopathy (no vs yes [coeliac absent] vs yes [coeliac present ≤2 cm]) and randomly assigned (1:1) to receive weekly intravenous paclitaxel (50 mg/m2 intravenously over 1 h) and carboplatin (area under the curve 2, intravenously over 30–60 min) for 6 weeks with radiotherapy 50·4 Gy in 28 fractions (chemoradiotherapy) followed by surgery, with or without intravenous trastuzumab (4 mg/kg in week one, 2 mg/kg per week for 5 weeks during chemoradiotherapy, 6 mg/kg once presurgery, and 6 mg/kg every 3 weeks for 13 treatments starting 21–56 days after surgery). The primary endpoint, disease-free survival, was defined as the time from randomisation to death or first of locoregional disease persistence or recurrence, distant metastases, or second primary malignancy. Analyses were done by modified intention to treat. This study is registered with Clinicaltrials.gov, NCT01196390; it is now closed and in follow-up. 606 patients were entered for HER2 assessment from Dec 30, 2010 to Nov 10, 2015, and 203 eligible patients who were HER2-positive were enrolled and randomly assigned to chemoradiotherapy plus trastuzumab (n=102) or chemoradiotherapy alone (n=101). Median duration of follow-up was 2·8 years (IQR 1·4–5·7). Median disease-free survival was 19·6 months (95% CI 13·5–26·2) with chemoradiotherapy plus trastuzumab compared with 14·2 months (10·5–23·0) for chemoradiotherapy alone (hazard ratio 0·99 [95% CI 0·71–1·39], log-rank p=0·97). Grade 3 treatment-related adverse events occurred in 41 (43%) of 95 patients in the chemoradiotherapy plus trastuzumab group versus 52 (54%) of 96 in the chemoradiotherapy group and grade 4 events occurred in 20 (21%) versus 21 (22%). The most common grade 3 or worse treatment-related adverse events for both groups were haematological (53 [56%] of 95 patients in the chemoradiotherapy plus trastuzumab group vs 55 [57%] of 96 patients in the chemotherapy group) or gastrointestinal disorders (28 [29%] vs 20 [21 %]). 34 (36%) of 95 patients in the chemoradiotherapy plus trastuzumab group and 27 (28%) of 96 patients in the chemoradiotherapy only group had treatment-related serious adverse events. There were eight treatment-related deaths: five (5%) of 95 patients in the chemoradiotherapy plus trastuzumab group (bronchopleural fistula, oesophageal anastomotic leak, lung infection, sudden death, and death not otherwise specified), and three (3%) of 96 in the chemoradiotherapy group (two multiorgan failure and one sepsis). The addition of trastuzumab to neoadjuvant chemoradiotherapy for HER2-overexpressing oesophageal cancer was not effective. Trastuzumab did not lead to increased toxicities, suggesting that future studies combining it with or using other agents targeting HER2 in oesophageal cancer are warranted." @default.
- W4226156918 created "2022-05-05" @default.
- W4226156918 creator A5001457923 @default.
- W4226156918 creator A5011233983 @default.
- W4226156918 creator A5013039829 @default.
- W4226156918 creator A5016694714 @default.
- W4226156918 creator A5017215021 @default.
- W4226156918 creator A5026796794 @default.
- W4226156918 creator A5030502605 @default.
- W4226156918 creator A5035857272 @default.
- W4226156918 creator A5035865205 @default.
- W4226156918 creator A5039395742 @default.
- W4226156918 creator A5044225007 @default.
- W4226156918 creator A5049977093 @default.
- W4226156918 creator A5062040958 @default.
- W4226156918 creator A5066810740 @default.
- W4226156918 creator A5070955874 @default.
- W4226156918 creator A5071668167 @default.
- W4226156918 creator A5071942279 @default.
- W4226156918 creator A5075359564 @default.
- W4226156918 creator A5083156203 @default.
- W4226156918 creator A5083203430 @default.
- W4226156918 creator A5085572029 @default.
- W4226156918 creator A5090936242 @default.
- W4226156918 date "2022-02-01" @default.
- W4226156918 modified "2023-10-14" @default.
- W4226156918 title "Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial" @default.
- W4226156918 cites W1922694287 @default.
- W4226156918 cites W1964321121 @default.
- W4226156918 cites W1969965083 @default.
- W4226156918 cites W1978013017 @default.
- W4226156918 cites W1987009448 @default.
- W4226156918 cites W2040935952 @default.
- W4226156918 cites W2092862243 @default.
- W4226156918 cites W2100439220 @default.
- W4226156918 cites W2115759102 @default.
- W4226156918 cites W2117223681 @default.
- W4226156918 cites W2136197678 @default.
- W4226156918 cites W2139984188 @default.
- W4226156918 cites W2146384083 @default.
- W4226156918 cites W2149908785 @default.
- W4226156918 cites W2172265576 @default.
- W4226156918 cites W2185378752 @default.
- W4226156918 cites W2318605753 @default.
- W4226156918 cites W2570401594 @default.
- W4226156918 cites W2598685895 @default.
- W4226156918 cites W2763498516 @default.
- W4226156918 cites W2767612092 @default.
- W4226156918 cites W2773022455 @default.
- W4226156918 cites W2892163061 @default.
- W4226156918 cites W2943492643 @default.
- W4226156918 cites W3024911178 @default.
- W4226156918 cites W3124418403 @default.
- W4226156918 cites W3137983013 @default.
- W4226156918 cites W3147820834 @default.
- W4226156918 cites W4236554935 @default.
- W4226156918 cites W4239989216 @default.
- W4226156918 cites W4293241248 @default.
- W4226156918 doi "https://doi.org/10.1016/s1470-2045(21)00718-x" @default.
- W4226156918 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35038433" @default.
- W4226156918 hasPublicationYear "2022" @default.
- W4226156918 type Work @default.
- W4226156918 citedByCount "50" @default.
- W4226156918 countsByYear W42261569182020 @default.
- W4226156918 countsByYear W42261569182021 @default.
- W4226156918 countsByYear W42261569182022 @default.
- W4226156918 countsByYear W42261569182023 @default.
- W4226156918 crossrefType "journal-article" @default.
- W4226156918 hasAuthorship W4226156918A5001457923 @default.
- W4226156918 hasAuthorship W4226156918A5011233983 @default.
- W4226156918 hasAuthorship W4226156918A5013039829 @default.
- W4226156918 hasAuthorship W4226156918A5016694714 @default.
- W4226156918 hasAuthorship W4226156918A5017215021 @default.
- W4226156918 hasAuthorship W4226156918A5026796794 @default.
- W4226156918 hasAuthorship W4226156918A5030502605 @default.
- W4226156918 hasAuthorship W4226156918A5035857272 @default.
- W4226156918 hasAuthorship W4226156918A5035865205 @default.
- W4226156918 hasAuthorship W4226156918A5039395742 @default.
- W4226156918 hasAuthorship W4226156918A5044225007 @default.
- W4226156918 hasAuthorship W4226156918A5049977093 @default.
- W4226156918 hasAuthorship W4226156918A5062040958 @default.
- W4226156918 hasAuthorship W4226156918A5066810740 @default.
- W4226156918 hasAuthorship W4226156918A5070955874 @default.
- W4226156918 hasAuthorship W4226156918A5071668167 @default.
- W4226156918 hasAuthorship W4226156918A5071942279 @default.
- W4226156918 hasAuthorship W4226156918A5075359564 @default.
- W4226156918 hasAuthorship W4226156918A5083156203 @default.
- W4226156918 hasAuthorship W4226156918A5083203430 @default.
- W4226156918 hasAuthorship W4226156918A5085572029 @default.
- W4226156918 hasAuthorship W4226156918A5090936242 @default.
- W4226156918 hasBestOaLocation W42261569182 @default.
- W4226156918 hasConcept C121608353 @default.
- W4226156918 hasConcept C126322002 @default.
- W4226156918 hasConcept C143998085 @default.
- W4226156918 hasConcept C2779786085 @default.
- W4226156918 hasConcept C2781182431 @default.
- W4226156918 hasConcept C530470458 @default.
- W4226156918 hasConcept C535046627 @default.